Table 1 Percentage of individuals in the sample by major socio-demographic characteristics and COVID vaccination history. Percentages in the last three columns add up to 100\(\%\) by character groupings (except the rows on specific vaccine types where the last column is not relevant). In the last section of rows, we classified the individuals by the accepted vaccine type.
From: Understanding hesitancy with revealed preferences across COVID-19 vaccine types
Evaluated all vaccines unacceptable (%) | Evaluated one vaccine acceptable but another unacceptable (%) | Vaccinated without rejection (%) | Vaccinated after rejection (%) | Non-vaccinated (%) | |
|---|---|---|---|---|---|
Men | 1.1 | 7.9 | 30.7 | 4.6 | 11.7 |
Women | 1.2 | 10.3 | 32.2 | 6.2 | 14.5 |
University | 0.2 | 3.4 | 14.4 | 2.9 | 4.3 |
High-school | 1.7 | 11.7 | 32.7 | 6.2 | 14.7 |
Elementary | 0.4 | 3.1 | 15.9 | 1.7 | 7.2 |
Not chronic Illness | 1.6 | 11.8 | 33.0 | 6.4 | 19.9 |
Chronic Illness | 0.7 | 6.4 | 29.9 | 4.4 | 6.3 |
Age 20–39 | 0.9 | 7.8 | 16.2 | 4.3 | 12.6 |
Age 40–59 | 0.8 | 5.9 | 20.6 | 3.4 | 9.2 |
Age 60–79 | 0.5 | 4.0 | 23.0 | 2.7 | 3.3 |
Age 80+ | 0.0 | 0.2 | 2.3 | 0.0 | 0.3 |
Pfizer | − | 5.0 | 20.3 | 5.8 | – |
Moderna | − | 0.8 | 3.5 | 1.0 | – |
AstraZeneca | − | 1.1 | 12.1 | 1.1 | – |
Sputnik | − | 1.4 | 12.3 | 1.3 | – |
Sinopharm | − | 1.5 | 14.7 | 1.6 | – |
